EGFR and non-small cell lung carcinoma: The LUX-Lung 3/6/7 trials revealed that afatinib had obvious effects in the treatment of advanced EGFR-mutant NSCLC [9–12] and might provide a better curative effect than first-generation EGFR-TKIs [13].